On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers

Carta A
First
Methodology
;Conversano C
Last
Conceptualization
2020-01-01
2020
pharmacoeconomics, cost-utility analysis, Markov models, Dengue fever, incremental cost effectiveness ratio, willingness to pay
Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie